BCAB · BioAtla, Inc.
$3.09
-0.36 (-10.43%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, and along with our history of operating losses, our current cash and cash equivalents are not sufficient to fund our ongoing operations for a period of at least twelve months from the date the condensed consolidated financial statements included in this report are issued, and these circumstances raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.15M
Shares
1.67M
BioAtla, Inc. Earnings Call Transcripts
Every quarterly earnings call for BioAtla, Inc. (BCAB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Earnings call
FY25 · Q3
2025-11-13
BioAtla, Inc. Q3 FY2025 Earnings Call
Confident tone
Phase 3 OSV Registrational Trial (OPSCC)
Market Opportunity / Commercial Prospects
Mecbotamab Vedotin (MEK-V) / MECD Program
Diluted EPS
$-13.50
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
BioAtla, Inc. Q2 FY2025 Earnings Call
Positive tone
BA3182 EPCAM CD3 T-cell engager
OSV (CAB-AXL ADC) head and neck cancer
Conference presentations and data readouts
Diluted EPS
$-15.99
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-05-07
Citizens Life Sciences Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-06
BioAtla, Inc. Q1 FY2025 Earnings Call
Positive tone
Mecbotamab Vedotin (CAB-AXL-ADC) in mKRAS NSCLC and sarcoma
Corporate partnerships and deal-making
Evalstotug (CAB-CTLA-4) in melanoma
Diluted EPS
$-13.16
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
BioAtla, Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
BioAtla, Inc. Q3 FY2024 Earnings Call
Confident tone
Ozuriftamab vedotin (CAB-ROR2-ADC) in head and neck cancer
Evalstotug (CAP CTLA-4) in melanoma
Cash runway and financing strategy
Diluted EPS
$-11.00
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
BioAtla, Inc. Q2 FY2024 Earnings Call
Positive tone
Evalstotug (CAB CTLA-4 antibody) safety and efficacy
Ozuriftamab vedotin (CAB-ROR2-ADC) in head and neck cancer
Mecbotamab vedotin (CAB-AXL-ADC) in NSCLC and KRAS
Diluted EPS
$-22.00
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
BioAtla, Inc. Q1 FY2024 Earnings Call
Positive tone
CAB-ROR2-ADC (ozuriftamab vedotin) in head and neck cancer
CAB CTLA-4 antibody (evalstotug) dose escalation
Nectin-4 ADC with carbohydrate linker
Diluted EPS
$-24.00
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
BioAtla, Inc. Q4 FY2023 Earnings Call
Confident tone
BA3071 CAB-CTLA-4 antibody
BA3021 CAB-ROR2-ADC
BA3011 CAB-AXL-ADC
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
BioAtla, Inc. Q3 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-35.00
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
BioAtla, Inc. Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-37.50
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
BioAtla, Inc. Q1 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-29.00
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
BioAtla, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
BioAtla, Inc. Q3 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-34.50
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
BioAtla, Inc. Q2 FY2022 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-38.50
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
BioAtla, Inc. Q1 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-32.50
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 earnings calls
Key facts
CIK
1826892
CUSIP
09077B203
13F (30d)
21 filings
21 filers
Visit website
Investor relations